Paola Alberti, MD, PhD

MD, PhD, Board in Neurology. Her main expertise is related to Chemotherapy Induced Peripheral Neurotoxicity (CIPN) at clinical and preclinical level (Scopus ID: 7103068082). She is a consultant Neurologist at San Gerardo Hospital (ASST Monza, Italy) as the treating physician for out-patients affected by CIPN (Ambulatorio di Fragilità Neurologica). She is the PI for the INTERNATIONAL CHEMOTHERAPY-INDUCED NEUROTOXICITY (CIPN) ASSESSMENT AND VALIDATION STUDY (ICAVS, NCT04633655) which involves 30 Centers around the globe (US, Canada, South America, Africa, India, Asia, Australia). She is also PI of the CIPN COST study (www.cipncare.com, NCT04986891), aiming at ascertaining socio-economic burden related to CIPN (awarded a 55,000 euros grant for 1st year and 60,000 for the 2nd year, by UNIMIB), and of the NEUPER study (NCT05088681), aiming at ascertain efficacy of physical treatment to reverse sensory ataxia due to polyneuropathy. At preclinical level she is investigating the role of ion channels in CIPN pathogenesis, applying morphological and neurophysiological techniques to CIPN rodent models and in vitro systems. She is also responsible for human anatomy teaching courses (at UNIMIB since 2016 and at Lunex University since 2020).

AWARDS AND GRANTS: Premio Giovani Talenti 2021 (first place, Accademia dei Lincei/University of Milano Bicocca); Bicocca starting grant (December 2020) as PI for the conduction of a 12 months research project focused on socio-economic burden related to (personal grant: 115,000 euros); Premio Giovani Talenti 2020 (second place, Accademia dei Lincei/University of Milano Bicocca); AIPN prize 2018 for the best oral presentation at the ASNP meeting 2018 (Rome, Italy) for the contribution: “Oxaliplatin Induced Peripheral Neurotoxicity: a rat model that reproduces acute and chronic phenomena”; second place at Falling Wall Labs 2017 among all Italian participants with the project “Breaking the wall of Chemotherapy Induced Peripheral Neurotox”,

ROLES IN NATIONAL/INTERNATIONAL SCIENTIFIC SOCIETIES: 2022 - Chair of the MASCC Neurological Complications study group, of the Multinational Association of Supportive Care in Cancer (MASCC), Canada; 2021 – Institutional panel member on the EAN Scientific Panel Neuroscience/translational neurology, Austria; 2021 – Vice chair of the PNS Junior board, and Toxic Neuropathy Consortium repr. of PNS, USA; 2020 – Co-chair of the CIPN working group of the MASCC, Canada.